Nevro Corp Company Profile (NYSE:NVRO)

About Nevro Corp (NYSE:NVRO)

Nevro Corp logoNevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Symbol: NYSE:NVRO
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.16 billion
  • Outstanding Shares: 29,295,000
Average Prices:
  • 50 Day Moving Avg: $83.97
  • 200 Day Moving Avg: $85.88
  • 52 Week Range: $66.55 - $106.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 820.44
  • P/E Growth: -2.99
Sales & Book Value:
  • Annual Revenue: $255.29 million
  • Price / Sales: 8.47
  • Book Value: $8.29 per share
  • Price / Book: 8.91
  • EBIDTA: ($25,290,000.00)
  • Net Margins: -18.91%
  • Return on Equity: -14.57%
  • Return on Assets: -9.98%
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 11.83%
  • Quick Ratio: 9.71%
  • Average Volume: 579,954 shs.
  • Beta: -0.75
  • Short Ratio: 10.75

Frequently Asked Questions for Nevro Corp (NYSE:NVRO)

What is Nevro Corp's stock symbol?

Nevro Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro Corp's earnings last quarter?

Nevro Corp (NYSE:NVRO) released its earnings results on Monday, May, 8th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.24. The company had revenue of $68.40 million for the quarter, compared to the consensus estimate of $68.71 million. Nevro Corp had a negative net margin of 18.91% and a negative return on equity of 14.57%. The firm's revenue was up 64.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.33) earnings per share. View Nevro Corp's Earnings History.

Where is Nevro Corp's stock going? Where will Nevro Corp's stock price be in 2017?

13 brokerages have issued 1-year price objectives for Nevro Corp's shares. Their forecasts range from $85.00 to $120.00. On average, they expect Nevro Corp's stock price to reach $101.90 in the next year. View Analyst Ratings for Nevro Corp.

What are analysts saying about Nevro Corp stock?

Here are some recent quotes from research analysts about Nevro Corp stock:

  • 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (5/11/2017)
  • 2. Northland Securities analysts commented, "The widely awaited release of Boston Scientific's ACCELERATE Study data on the Q4 call today, was a downer. Strangely enough, the company stated on its call that it "would continue enrolling patients in the trial, expects enrollment to finish by end of FY17, and data release by mid-2018." Suffice it to say, the anti-climax will be perceived as something being off in the ACCELERATE Study, hence being positive for Nevro."The analyst speculated that something is off in the ACCELERATE study, causing a delay in datarelease. Here are some thoughts / questions:Is Boston Sci increasing the sample size in the trial ?Was there a sub-group analysis done and investigators realized that the bellcurve on lead placements was not on T8 - T10 locations, hence pain relief was sub-optimal? Will there now be more anatomical placement on T8 - T10 with its HF arm? In essence, is Boston Sci converging on Nevro's "secret sauce" (2/2/2017)

Who are some of Nevro Corp's key competitors?

Who owns Nevro Corp stock?

Nevro Corp's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (7.55%), Vanguard Group Inc. (6.63%), BlackRock Inc. (5.40%), Goldman Sachs Group Inc. (5.07%), Alliancebernstein L.P. (4.19%) and OppenheimerFunds Inc. (2.64%). Company insiders that own Nevro Corp stock include & Johnson Johnson, Andre Walker, Andrew H Galligan, Bay City Capital Llc, Brad Vale, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro Corp.

Who sold Nevro Corp stock? Who is selling Nevro Corp stock?

Nevro Corp's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY, FMR LLC, Next Century Growth Investors LLC, Alliancebernstein L.P., American Century Companies Inc., Wellington Management Group LLP, Artisan Partners Limited Partnership and Kornitzer Capital Management Inc. KS. Company insiders that have sold Nevro Corp stock in the last year include Andre Walker, Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Insider Buying and Selling for Nevro Corp.

Who bought Nevro Corp stock? Who is buying Nevro Corp stock?

Nevro Corp's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Perceptive Advisors LLC, Janus Capital Management LLC, OppenheimerFunds Inc., Gilder Gagnon Howe & Co. LLC, Columbus Circle Investors and Blue Jay Capital Management LLC. View Insider Buying and Selling for Nevro Corp.

How do I buy Nevro Corp stock?

Shares of Nevro Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nevro Corp stock cost?

One share of Nevro Corp stock can currently be purchased for approximately $73.84.

Analyst Ratings

Consensus Ratings for Nevro Corp (NYSE:NVRO) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $101.90 (38.00% upside)

Analysts' Ratings History for Nevro Corp (NYSE:NVRO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017ValuEngineDowngradeHold -> SellLowView Rating Details
5/14/2017B. RileyDowngradeNeutral$85.00LowView Rating Details
5/9/2017Northland SecuritiesReiterated RatingBuy$96.00HighView Rating Details
3/23/2017Canaccord GenuityInitiated CoverageBuy$120.00MediumView Rating Details
2/24/2017Leerink SwannBoost Price TargetOutperform$100.00 -> $110.00N/AView Rating Details
8/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$98.00 -> $112.00N/AView Rating Details
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$84.00 -> $100.00N/AView Rating Details
8/9/2016JMP SecuritiesBoost Price TargetMarket Outperform$90.00 -> $110.00N/AView Rating Details
8/9/2016BMO Capital MarketsReiterated RatingBuy$100.00N/AView Rating Details
8/8/2016Bank of America CorpInitiated CoverageBuy$100.00N/AView Rating Details
7/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
7/12/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
6/29/2016Morgan StanleyReiterated RatingBuy$86.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Nevro Corp (NYSE:NVRO)
Earnings by Quarter for Nevro Corp (NYSE:NVRO)
Earnings History by Quarter for Nevro Corp (NYSE:NVRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.26)($0.50)$68.71 million$68.40 millionViewListenView Earnings Details
2/23/2017Q416($0.20)($0.34)$66.41 million$70.50 millionViewN/AView Earnings Details
11/7/2016Q316($0.39)($0.14)$58.05 million$60.92 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.31)$45.11 million$55.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.65)($0.33)$33.48 million$41.65 millionViewN/AView Earnings Details
2/29/2016Q415($0.56)($0.51)$32.88 million$33.10 millionViewListenView Earnings Details
11/9/2015Q315($0.75)($0.70)$12.51 million$15.40 millionViewN/AView Earnings Details
8/6/2015Q215($0.89)($0.77)$9.65 million$11.40 millionViewN/AView Earnings Details
5/11/2015Q1($0.54)($0.57)$8.20 million$9.66 millionViewListenView Earnings Details
3/18/2015Q4 2014($0.51)($0.59)$9.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nevro Corp (NYSE:NVRO)
Current Year EPS Consensus Estimate: $-0.99 EPS
Next Year EPS Consensus Estimate: $0.09 EPS


Dividend History for Nevro Corp (NYSE:NVRO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Nevro Corp (NYSE:NVRO)
Insider Ownership Percentage: 12.10%
Insider Trades by Quarter for Nevro Corp (NYSE:NVRO)
Institutional Ownership by Quarter for Nevro Corp (NYSE:NVRO)
Insider Trades by Quarter for Nevro Corp (NYSE:NVRO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Andrew H. GalliganCFOSell7,500$75.30$564,750.00View SEC Filing  
5/2/2017Michael F DemaneDirectorSell29,800$96.07$2,862,886.00View SEC Filing  
5/1/2017Rami ElghandourCEOSell10,000$95.03$950,300.00View SEC Filing  
4/4/2017Michael EnxingVPSell1,500$93.53$140,295.00View SEC Filing  
4/4/2017Michael F DemaneDirectorSell22,200$93.39$2,073,258.00View SEC Filing  
4/3/2017Andrew H. GalliganCFOSell30,000$94.46$2,833,800.00View SEC Filing  
3/6/2017Michael EnxingVPSell38,500$91.01$3,503,885.00View SEC Filing  
3/3/2017Wilfred E JaegerDirectorSell43,980$95.03$4,179,419.40View SEC Filing  
1/4/2017Michael EnxingVPSell1,500$75.88$113,820.00View SEC Filing  
12/5/2016Michael EnxingVPSell1,500$76.38$114,570.00View SEC Filing  
11/15/2016Andrew H GalliganCFOSell7,500$86.90$651,750.00View SEC Filing  
10/10/2016Rami ElghandourCEOSell3,000$100.00$300,000.00View SEC Filing  
10/6/2016Michael F DemaneDirectorSell139,514$97.46$13,597,034.44View SEC Filing  
10/4/2016Michael EnxingVPSell1,500$99.31$148,965.00View SEC Filing  
8/22/2016Doug AlleavitchVPSell3,000$100.00$300,000.00View SEC Filing  
8/22/2016Wilfred E JaegerDirectorSell154,840$97.79$15,141,803.60View SEC Filing  
8/17/2016Wilfred E JaegerDirectorSell155,160$97.31$15,098,619.60View SEC Filing  
8/15/2016Andrew H GalliganCFOSell7,500$97.71$732,825.00View SEC Filing  
8/10/2016Doug AlleavitchVPSell2,500$95.00$237,500.00View SEC Filing  
8/9/2016Michael F DemaneDirectorSell26,667$91.50$2,440,030.50View SEC Filing  
8/4/2016Michael EnxingVPSell1,500$82.06$123,090.00View SEC Filing  
7/29/2016Doug AlleavitchVPSell1,000$85.00$85,000.00View SEC Filing  
7/29/2016Michael F DemaneDirectorSell13,333$84.00$1,119,972.00View SEC Filing  
7/11/2016Doug AlleavitchVPSell2,000$80.00$160,000.00View SEC Filing  
7/11/2016Michael F DemaneDirectorSell13,333$79.00$1,053,307.00View SEC Filing  
7/5/2016Michael EnxingVPSell1,500$75.39$113,085.00View SEC Filing  
7/1/2016Michael F DemaneDirectorSell13,333$74.00$986,642.00View SEC Filing  
6/8/2016Doug AlleavitchVPSell1,000$75.00$75,000.00View SEC Filing  
6/8/2016Rami ElghandourCEOSell7,000$76.59$536,130.00View SEC Filing  
6/6/2016Michael EnxingVPSell1,500$73.29$109,935.00View SEC Filing  
6/2/2016Andre WalkerVPSell4,000$73.50$294,000.00View SEC Filing  
6/1/2016Doug AlleavitchVPSell500$72.00$36,000.00View SEC Filing  
5/18/2016Wilfred E JaegerDirectorSell112,983$64.68$7,307,740.44View SEC Filing  
5/16/2016Andrew H GalliganCFOSell10,000$64.78$647,800.00View SEC Filing  
5/16/2016Michael F DemaneCEOSell39,999$64.77$2,590,735.23View SEC Filing  
5/12/2016Rami ElghandourPresidentSell7,000$63.93$447,510.00View SEC Filing  
5/4/2016Michael EnxingVPSell1,500$65.06$97,590.00View SEC Filing  
4/4/2016Michael EnxingVPSell8,767$61.59$539,959.53View SEC Filing  
4/1/2016Rami ElghandourPresidentSell7,000$60.99$426,930.00View SEC Filing  
1/11/2016Andre WalkerVPSell7,987$70.75$565,080.25View SEC Filing  
1/4/2016Doug AlleavitchVPSell2,514$66.47$167,105.58View SEC Filing  
12/17/2015Andre WalkerVPSell13$69.00$897.00View SEC Filing  
12/7/2015Rami ElghandourPresidentSell3,500$61.82$216,370.00View SEC Filing  
12/2/2015Andre WalkerVPSell1,000$64.00$64,000.00View SEC Filing  
12/1/2015Andre WalkerVPSell8,000$59.50$476,000.00View SEC Filing  
11/30/2015Andre WalkerVPSell6,000$58.50$351,000.00View SEC Filing  
11/30/2015Rami ElghandourPresidentSell3,500$60.00$210,000.00View SEC Filing  
11/24/2015Andre WalkerVPSell1,000$55.00$55,000.00View SEC Filing  
11/23/2015Andre WalkerVPSell1,000$54.00$54,000.00View SEC Filing  
11/23/2015Wilfred E JaegerDirectorSell25,000$53.48$1,337,000.00View SEC Filing  
11/18/2015Wilfred E JaegerDirectorSell175,000$52.24$9,142,000.00View SEC Filing  
11/16/2015Michael F DemaneCEOSell26,667$50.52$1,347,216.84View SEC Filing  
11/13/2015Brad ValeDirectorBuy2,000$50.76$101,520.00View SEC Filing  
9/17/2015Andre WalkerVPSell4,000$50.75$203,000.00View SEC Filing  
9/2/2015Michael F DemaneCEOSell40,001$45.11$1,804,445.11View SEC Filing  
6/8/2015& Johnson JohnsonMajor ShareholderSell1,010,265$47.94$48,432,104.10View SEC Filing  
6/8/2015Bay City Capital LlcInsiderSell491,835$47.94$23,578,569.90View SEC Filing  
6/8/2015Wilfred E JaegerDirectorSell393,468$47.94$18,862,855.92View SEC Filing  
11/12/2014& Johnson JohnsonMajor ShareholderBuy40,000$18.00$720,000.00View SEC Filing  
11/12/2014A/S NovoInsiderBuy215,000$18.00$3,870,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Nevro Corp (NYSE:NVRO)
Latest Headlines for Nevro Corp (NYSE:NVRO)
DateHeadline logoNevro Corp (NVRO) Downgraded by ValuEngine to Sell - May 24 at 3:56 PM logoZacks: Analysts Anticipate Nevro Corp (NVRO) Will Announce Quarterly Sales of $73.83 Million - May 17 at 12:02 PM logoNevro Corp (NVRO) CFO Sells $564,750.00 in Stock - May 16 at 7:33 PM logo-$0.28 EPS Expected for Nevro Corp (NVRO) This Quarter - May 15 at 9:24 AM logoB. Riley Downgrades Nevro Corp (NVRO) to Neutral - May 14 at 10:16 AM logoNevro Corp (NVRO) Given Consensus Recommendation of "Buy" by Brokerages - May 12 at 7:40 AM logoNevro Corp (NVRO) Stock Rating Lowered by Zacks Investment Research - May 11 at 8:04 AM logoEdited Transcript of NVRO earnings conference call or presentation 8-May-17 8:30pm GMT - May 10 at 11:59 AM logoOversold Conditions For Nevro (NVRO) - May 9 at 6:32 PM logoNevro Corp. Just Tumbled By As Much As 12% -- Here's Why - May 9 at 6:32 PM logoMedtech Player Losses Double That Of Views; Shares Tumble - May 9 at 6:32 PM logoNevro Corp (NVRO) Releases Quarterly Earnings Results, Misses Expectations By $0.24 EPS - May 9 at 4:02 PM logoNevro Corp (NVRO) Rating Reiterated by Northland Securities - May 9 at 11:32 AM logoB. Riley Downgrades Nevro Corp (NVRO) to Neutral Citing Slower US-Based Revenue Growth - May 9 at 11:26 AM logoNevro Reports First Quarter 2017 Financial Results - May 8 at 6:23 PM logoNevro reports 1Q loss - May 8 at 4:34 PM logoMedical Product Q1 Earnings on May 8: ITGR, OPK & More - May 5 at 7:13 PM logoNevro Corp (NVRO) Receives Media Impact Score of -0.08 - May 4 at 12:08 PM logoRami Elghandour Sells 10,000 Shares of Nevro Corp (NVRO) Stock - May 3 at 7:00 PM logoMichael F. Demane Sells 29,800 Shares of Nevro Corp (NVRO) Stock - May 3 at 6:56 PM logoNevro to Present at the Bank of America Merrill Lynch 2017 Health Care Conference - Yahoo Finance - May 2 at 4:44 PM logoNevro to Present at the Bank of America Merrill Lynch 2017 Health Care Conference - May 2 at 4:44 PM logoNevro Corp. – Value Analysis (NYSE:NVRO) : May 1, 2017 - May 1 at 5:52 PM logoNevro Corp (NVRO) Earning Somewhat Favorable Media Coverage, Report Finds - April 30 at 9:40 AM logoNevro Corp. breached its 50 day moving average in a Bullish Manner : NVRO-US : April 28, 2017 - April 28 at 8:46 AM logo$68.09 Million in Sales Expected for Nevro Corp (NVRO) This Quarter - April 26 at 12:16 PM logoNevro to Report Operating Results for the First Quarter 2017 - April 25 at 5:43 AM logo-$0.26 EPS Expected for Nevro Corp (NVRO) This Quarter - April 24 at 4:24 PM logoNevro Corp (NVRO) Earns Daily Coverage Optimism Score of -0.20 - April 24 at 2:01 PM logoETFs with exposure to Nevro Corp. : April 21, 2017 - April 21 at 6:48 PM logoNevro Corp (NVRO) Receiving Somewhat Negative Press Coverage, Analysis Shows - April 21 at 5:48 PM logoNevro Corp (NVRO) Receives Consensus Recommendation of "Buy" from Brokerages - April 17 at 10:14 AM logoNevro Corp (NVRO) Receiving Somewhat Positive Media Coverage, Analysis Shows - April 15 at 2:55 PM logoNevro Becomes Oversold (NVRO) - April 12 at 7:52 PM logoETFs with exposure to Nevro Corp. : April 7, 2017 - April 7 at 7:21 PM logoNevro Corp. breached its 50 day moving average in a Bearish Manner : NVRO-US : April 6, 2017 - April 7 at 11:38 AM logoMichael Enxing Sells 1,500 Shares of Nevro Corp (NVRO) Stock - April 5 at 8:52 PM logoInsider Selling: Nevro Corp (NVRO) CFO Sells 30,000 Shares of Stock - April 5 at 8:04 PM logoNevro Corp (NVRO) Director Michael F. Demane Sells 22,200 Shares - April 5 at 8:03 PM logoNevro: Increased Access To HF10 Therapy Will Power Stock Price - March 29 at 7:37 PM logoNevro Corp (NVRO) Now Covered by Canaccord Genuity - March 29 at 8:47 AM logoCanaccord Genuity Begins Coverage on Nevro Corp (NVRO) - March 29 at 8:41 AM logoCommit To Purchase Nevro Corp At $75, Earn 10.2% Annualized Using Options - March 27 at 6:26 PM logoNevro Corp (NVRO) Now Covered by Analysts at Canaccord Genuity - March 23 at 2:10 PM logoRecent Developments in the Electrophysiology Markets - March 22 at 9:10 AM logoNevro Corp (NVRO) Given Consensus Rating of "Buy" by Analysts - March 21 at 12:34 PM logoBlog Coverage German and UK Courts Rule in Favor of Boston Scientifics' Patent Related Litigation with Edwards Lifesciences - March 10 at 9:22 AM logoNEVRO CORP Financials - March 1 at 7:07 PM logoNevro Corp (NVRO) PT Raised to $110 at Leerink Partners - - February 24 at 8:55 AM logoEdited Transcript of NVRO earnings conference call or presentation 23-Feb-17 9:30pm GMT - February 24 at 8:55 AM



Nevro Corp (NVRO) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff